Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IPH4502 in Cancer, Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
9/23/24- IND clearance from the FDA. 1/27/25- First patient dosed. 11/12/25:- IPH4502 Ph1 dose escalation enrolling well; pharmacologic activity reached; dose-escalation data in H1 2026. 03/25/26:- IPH4502 Ph1 shows preliminary anti-tumor activity; cohort enrichment ongoing; H1 2026 dose-escalation data expected. 05/12/26:- IPH4502 Ph1 MTD reached; dose-escalation and enrichment enrollment near complete; H1 2026 data readout reiterated. 07/20/26:- Enrollment complete; Year-End 2026 preliminary readout. Favorable safety; responses in post-EV UC, NSCLC, HNSCC. 08/10/26:- Phase 1 enrollment completed. Clinical results anticipated in 2026.
Verification
Confirm timing and program details against the company announcement or filing.